A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients—The ALPADIR Study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
AIMS: Alcohol dependence is a major public health issue with a need for new pharmacological treatments. The ALPADIR study assessed the efficacy and safety of baclofen at the target dose of 180 mg/day for the maintenance of abstinence and the reduction in alcohol consumption in alcohol-dependent patients. METHODS: Three hundred and twenty adult patients (158 baclofen and 162 placebo) were randomized after alcohol detoxification. After a 7-week titration, the maintenance dose was provided for 17 weeks, then progressively decreased over 2 weeks before stopping. RESULTS: The percentage of abstinent patients during 20 consecutive weeks (primary endpoint) was low (baclofen: 11.9%; placebo: 10.5%) and not significantly different between groups (OR 1.20; 95%CI: 0.58 to 2.50; P = 0.618). A reduction in alcohol consumption was observed from month 1 in both groups, but the difference of 10.9 g/day at month 6 between groups, in favour of baclofen, was not statistically significant (P = 0.095). In a subgroup of patients with high drinking risk level at baseline, the reduction was greater with a difference at month 6 of 15.6 g/day between groups in favour of baclofen (P = 0.089). The craving assessed with Obsessive-Compulsive Drinking Scale significantly decreased in the baclofen group (P = 0.017). No major safety concern was observed. CONCLUSIONS: This study did not demonstrate the superiority of baclofen in the maintenance of abstinence at the target dose of 180 mg/day. A tendency towards a reduction in alcohol consumption and a significantly decreased craving were observed in favour of baclofen. SHORT SUMMARY: Baclofen was assessed versus placebo for maintenance of abstinence and reduction in alcohol consumption in alcohol-dependent patients. This study did not demonstrate the superiority of baclofen in the maintenance of abstinence. A tendency towards a reduction in alcohol consumption and a significantly decreased craving were observed in favour of baclofen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The size and burden of mental disorders and other disorders of the brain in Europe 2010
Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jönsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.07.018 · Cited by 3,754 · cited 1×
“A 3.4% of the European population suffers from alcohol dependence (Wittchen et al., 2011; Rehm et al., 2015).”
BackgroundInfluentialChronic diseases and conditions related to alcohol use
Shield, K. (2013) · Alcohol Research: Current Reviews · doi:10.35946/arcr.v35.2.06 · Cited by 488 · cited 10×
“The heterogeneity of the AUD population and the different designs and methodologies, in terms of dose, duration of treatment, duration of detoxification, intensity of psychosocial support, endpoints and sample size, may explain the inconsistent results of these baclofen randomized studies.”
BackgroundInfluentialMissing Data in Alcohol Clinical Trials: A Comparison of Methods
Hallgren, K. A., & Witkiewitz, K. (2013) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12205 · Cited by 176 · cited 2×
“…mixture model (assuming that the alcohol consumption of dropped out patients was the same as those in the placebo group) was the main imputation method; it is one of the recommended method for handling missing data in alcohol clinical trials (Hallgren and Witkiewitz, 2013; Witkiewitz et al., 2014).”
MethodThe Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Self-citationWitkiewitz, K., Falk, D. E., Kranzler, H. R., Litten, R. Z., Hallgren, K. A., O'Malley, S. S., Anton, R. F., & Workgroup, I. C. W. T. A. C. T. I. (. (2014) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12543 · Cited by 60 · cited 2×
“…mixture model (assuming that the alcohol consumption of dropped out patients was the same as those in the placebo group) was the main imputation method; it is one of the recommended method for handling missing data in alcohol clinical trials (Hallgren and Witkiewitz, 2013; Witkiewitz et al., 2014).”
Method
Cited by
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review
Kranzler, H. R., & Soyka, M. (2018) · JAMA · doi:10.1001/jama.2018.11406 · Cited by 580
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective
de Beaurepaire, R., Sinclair, J. M. A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E. M., Caputo, F., Chick, J. D., de La Selle, P., Franchitto, N., et al. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00708 · Cited by 95
Self-citationBaclofen for alcohol use disorder
Minozzi, S., Saulle, R., & Rösner, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012557.pub2 · Cited by 73
Metadata
- Authors
- Reynaud, M., Aubin, H.-J., Trinquet, F., Zakine, B., Dano, C., Dematteis, M., Trojak, B., Paille, F., & Detilleux, M.
- Venue
- Alcohol and Alcoholism
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-19
- Volume
- 52
- Issue
- 4
- Pages
- 439-446
- ISSN
- 0735-0414 (ISSN-L)
- 1464-3502
- OpenAlex
- W2615387563
- Cited by
- 145
- References
- 5
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients—The ALPADIR Study. https://app.cochat.ai/papers/10.1093/alcalc/agx030
- The paper
- Reynaud, M., Aubin, H.-J., Trinquet, F., Zakine, B., Dano, C., Dematteis, M., Trojak, B., Paille, F., & Detilleux, M. (2017). A Randomized, Placebo-Controlled Study of High-Dose Baclofen in Alcohol-Dependent Patients—The ALPADIR Study. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agx030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.